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calcium and vitamin D-supplemented 
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with osteopenia or osteoporosis: data 
from Arzoxifene Generations Trial
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ABSTRACT 
Objective: Vertebral fracture is the most common osteoporotic fracture, affecting quality of 
life and increasing mortality. Epidemiological data on incidence of vertebral fracture are 
scarce in Brazil and throughout Latin America. Our aim was to determine vertebral fracture 
incidence and risk factors in a female Brazilian population. Subjects and methods: Postmenopausal 
women with low bone mass were studied from the Brazilian placebo group of Arzoxifene Generations 
Trial (n = 974), followed for up to 5 years. The primary endpoint was new vertebral fractures, detected 
by X-Ray. Experimental design defined two strata: A. Osteoporosis or previous vertebral fracture with 
osteopenia; B. Osteopenia without previous fracture. Previous fracture, T-score, ionized calcium, al-
kaline phosphatase, creatinine and glucose were analyzed at baseline. Crude and adjusted incidence 
rates of vertebral fractures were estimated and Poisson regression model was used. Results: Inci-
dence rate was 7.7 (95% CI of 5.4 to 10.9) per 1,000 person-years (PY), increasing as a function of 
age. Women with new vertebral fractures had higher prevalence of previous nonvertebral fracture 
after menopause, were older and had lower lumbar spine (LS) T-score. Fracture risk increased by 46% 
for each unit reduction in LS T-score. Variables correlated with new vertebral fracture were age (p = 
0.034), LS T-score, stratum A (p = 0.001 for both) and previous nonvertebral fracture after menopause 
(p = 0.019). In the final model, LS T-score was the strongest predictor. Conclusions: Incidence rate of 
vertebral fracture of 7.7 per 1,000 PY. Age and previous fractures were associated with new vertebral 
fracture, but LS T-score was the most important predictor. Arch Endocrinol Metab. 2016;60(1):54-9
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INTRODUCTION
O steoporosis is characterized by low bone mass and microarchitectural abnormalities, that to-
gether increase fragility fracture risk (1). It is a se rious 
public health problem that will get worse with the 
gradual aging of the world’s population (2). Vertebral 
fractures, a hallmark of osteoporosis, are the most 
common type of osteoporotic fracture (3), although 
only 1/3 of them are detected by an overt clinical 
event such as acute back pain (4). Besides, many 
vertebral fractures seen by X-ray or other imaging 
modality are not reported. In Latin America, 46.5% 
of vertebral fractures identifiable by X-ray are not 
recognized (5). However, vertebral fractures, even 
if asymptomatic, are associated with an increase in 
morbidity and mortality (6-11). 
Knowledge of the epidemiology of osteoporotic 
fractures is of fundamental importance for the planning 
of preventive actions and treatment strategies, but the-
se data are scarce, not only in Brazil but in all of Latin 
America. Brazil has a complex ethnic background with 
high level of miscegenation, resulting in a demographic 
blending of Native American Indians, Africans and La-
tino-Europeans who immigrated in the last few centu-
ries, with almost 24 million people over 60 years old 
(12). It is estimated that by 2060, the population 
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over 60 will increase by more than 3-fold, to 73.5 
million (12). Thus, acknowledged risk factors for os-
teoporotic fracture gleaned from more homogeneous 
populations may not apply to Brazil. 
The placebo arm of Arzoxifene Generations Trial 
(13), which had fracture detection as a main outcome 
measure, provided a convenience sample to investigate 
the incidence of osteoporotic fractures in naïve Brazi-
lian postmenopausal women living in different regions 
of the country. To our knowledge, this is the first study 
to investigate vertebral fracture incidence in almost 
1,000 postmenopausal women with low bone mass, 
aged between 60 to 85 years old, from multiple cen-
ters in Brazil. The results highlight the importance 
of several risk factors in this cohort that was followed 
prospectively for 5-years. 
SUBJECTS AND METHODS
This protocol was approved by the Ethics Committee 
of São Paulo Federal University (CEP 0972/2015). 
The placebo data were obtained from the Brazilian arm 
of the Arzoxifene Generations Trial (n = 974), funded 
by Eli Lilly and Company; ClinicalTrials.gov number, 
NCT00088010, which comprised of postmenopausal 
women with low bone mass, 60-85 years old, followed 
for up to 5 years, from 6 Brazilian cities distributed in 
3 Brazil regions: Northeast (Recife and Salvador, n = 
161), Southeast (Rio de Janeiro and Sao Paulo, n = 
723), and South (Curitiba and Porto Alegre, n = 90). 
In this trial, women were divided in two strata: Stratum 
A (n = 648) was comprised of women with a femoral 
neck or lumbar spine with osteoporosis (bone mineral 
density (BMD) T-score of -2.5 or less (73.4% of this 
stratum) or women with a vertebral fracture at baseline 
and osteopenia (26.6% of this stratum). Stratum B (n 
= 326) was comprised of women whose femoral neck 
and lumbar spine osteopenia (T-scores were between 
-1.0 and -2.5) without a vertebral fracture at baseline. 
New vertebral fractures were assessed by lateral spinal 
radiographs at 6, 12, 24, 36 and in the last visit (at 60 
months) for those patients in Stratum A and at baseli-
ne, 36 months and in the last visit (at 60 months) for 
those in Stratum B. Follow-up of this protocol was de-
signed until 60 months or until the first fracture event 
(vertebral or nonvertebral). For example, if a patient 
had a fracture after one year of follow-up, the time to 
fracture was used to evaluate the incidence of fractu-
re. Spinal radiographs were assessed independently by 
two readers at a central facility (Synarc) using a semi-
quantitative scale (14). This method is more efficient 
to perform than other methods of vertebral fracture 
assessment, suited to both clinical therapeutic efficacy 
trials and epidemiological research studies. It is easy to 
implement in clinical practice, as well as demonstrating 
excellent inter-reader reliability, as shown in a recent 
Brazilian paper, with agreement of 95% between inter-
reader (15). The evaluator scale is graded from normal 
(grade 0) to severe (grade 3). Grade 1 (mild) vertebral 
fracture corresponds to a 20-25% reduction in anterior, 
middle, and/or posterior height compared to normal 
adjacent vertebrae or compared to expected height of 
the vertebral body based on experience. Grade 2 (mo-
derate) vertebral fracture is a 25-40% reduction in ver-
tebral height, while grade 3 (severe) vertebral fracture is 
a more than 40% reduction in vertebral height.
A new vertebral fracture was defined as a change 
from normal to grade 1, 2 or 3 on any subsequent ra-
diograph. If two readers did not agree, the final de-
termination was adjudicated by a third reader. Other 
details of the design of the study, recruitment, as well 
as exclusion criterion were previously published (13). 
All patients received daily supplements containing ap-
proximately 500 mg of elemental calcium and 400 to 
600 IU of vitamin D. The primary endpoint analyzed 
in this study was new morphometric vertebral fractures, 
as assessed by X-Ray. 
Baseline clinical and laboratories parameters were 
analyzed, including age, postmenopausal duration, 
previous fracture in the last 5 years or fracture after 
menopause. Fasting measurements were made of the 
following indices: creatinine, glucose, ionized calcium, 
alkaline phosphatase, 25 hydroxyvitamin D (DiaSorin 
(formerly Incstar Corporation, Stillwater, MN)), and 
bone turnover markers (P1NP and CTX) in a subset of 
patients (n = 307). BMD at the proximal femur and 
lumbar spine was evaluated by dual-energy X-ray ab-
sorptiometry (DXA). We had no access to smoking 
and alcohol abuse prevalence in these patients. 
Statistical analyses were performed using STATA 
software (version 10.0, Stata Corp. College Station, 
USA). Mean and Standard Deviation (SD) were cal-
culated for each continuous variable and percentage 
for categorical ones. Chi-square or Fisher’s Exact Test 
for categorical variables and Student’s t-test for con-
tinuous variables was used to compare differences in 
the baseline measures from patients with new vertebral 
fractures to those who did not. Crude and adjusted in-
Co
py
rig
ht
©
 A
E&
M
 a
ll r
ig
ht
s r
es
er
ve
d.
56
Vertebral fractures in patients with low bone mass
Arch Endocrinol Metab. 2016;60/1
cidence rates of vertebral fractures were estimated by 
point and 95% confidence interval according to age and 
lumbar spine T-score categories. Incidence rate ratios 
were obtained to evaluate any association between risk 
factors and new vertebral fracture. The influence of the 
variables measured on the risk of incident fracture was 
analyzed using a Poisson regression model and the best 
fitting model obtained. All variables with a p-value of 
0.20 in the univariate analysis were included in the re-
gression full model. Only the statistically significant va-
riables remained in the final model. A p-value of < 0.05 
was considered to be significant.
RESULTS
During a follow-up period of up to 5 years, 31 new 
vertebral fractures were detected. Table 1 shows the ba-
seline characteristics of patients with and without new 
vertebral fractures. 
Postmenopausal women with incident vertebral 
fractures were older, had lower lumbar spine T-scores 
and had a prevalence of previous nonvertebral fractu-
re that was three times greater than the prevalence of 
previous nonvertebral fracture in patients without in-
cident vertebral fracture. The distribution of patients 
with new symptomatic or non-symptomatic vertebral 
fracture was not associated with the grade of the fractu-
re. The overall incidence rate of vertebral fractures, as 
determined by the semiquantitative scale of Genant and 
cols. was 7.7 (95% CI of 5.4 to 10.9) per 1,000 person- 
years (PY), increasing as a function of age. Patients be-
tween 75-79 years had a 3.5 fold higher incidence rate 
ratio of vertebral fracture as compared to the younger 
group 60-64 years (p = 0.02), as shown in Figure 1. 
We could not ascertain fracture incidence accurately in 
those between 80 to 85 years because there were only 
21 subjects in this age bracket. 
As expected, there was an inverse correlation bet-
ween lumbar spine T-score and the risk of incident ver-
tebral fracture. For each SD decrease in lumbar spine 
T-score, the risk of fracture increased by 46% (CI 22 
– 62%; p = 0.001). Moreover, women with osteoporosis 
or low bone mass with previous vertebral fracture (Stra-
tum A) had 3.9 times more new fractures than those 
with osteopenia (Stratum B) (p = 0.001). Twenty-six 
point six percent of all sustained vertebral fractures oc-
curred in patients without a densitometric osteoporosis 
(Stratum A). Nevertheless, of all new vertebral fractures, 
87% occurred in patients with osteoporosis (Figure 2). 
Based on the Poisson regression analysis, the varia-
bles correlated with new vertebral fracture included age 
(p = 0.034), lumbar spine T-score (p = 0.001), stratum 
A (p = 0.001) and previous nonvertebral fracture after 
menopause (p = 0.019). For the regression full model, 
Table 1. Baseline characteristics of postmenopausal women by new vertebral fracture 
Variable Overall N
With new 
vertebral 
fracture
N
Without new 
vertebral 
fracture
N p-value
Age, years (SD) 67.1 (5.2) 974 69.0 (5.1) 31 67.0 (5.2) 943 0.034
BMI, kg/m2 26.9 (4.4) 974 26.6 (4.0) 31 26.9 (4.4) 943 0.670
Previous vertebral fracture, n (%) (14%) 974 (26%) 31 (14%) 943 0.062
Previous nonvertebral fracture, n (%) (30%) 974 (45%) 31 (30%) 943 0.065
Previous nonvertebral postmenop. fracture n(%) (4%) 974 (13%) 31 (4%) 943 0.019
Previous fragility fracture in the last 5 y (16%) 974 (23%) 31 (16%) 943 0.172
T-score spine -2.5 (1.0) 974 -3.1 (0.8) 31 -2.5 (1.0) 943 0.001
T-score neck -1.8 (0.7) 974 -1.8 (0.7) 31 -1.8 (0.7) 943 0.705
T-score total hip -1.4 (0.9) 869 -1.6 (0.8) 30 -1.4 (0.9) 839 0.243
Calcium, mmol/L 2.42 (0.09) 974 2.40 (0.08) 31 2.42 (0.09) 943 0.160
Glucose, nmol/L 5.6 (1.71) 937 5.2 (0.9) 30 5.6 (1.7) 907 0.218
Alkaline phosphatase, U/L 83.9 (23.0) 974 80.4 (25.6) 31 84.0 (22.9) 943 0.384
25OHD, nmol/L 68.02 (22.16) 969 72.7 (21.4) 30 67.8 (22.2) 939 0.229
P1NP, μg/L 50.1 (20.6) 307 56.1 (26.0) 14 49.8 (20.3) 293 0.270
CTX, ng/mL 0.606 (0.270) 307 0.672 (0.282) 14 0.602 (0.269) 293 0.349
Creatinine, μmol/L 69.5 (13.5) 974 69.1 (12.2) 31 69.5 (13.5) 943 0.893
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Figure 1. Incidence trends of vertebral fracture (by 1,000 person-years) 
according to different age groups. Dotted line represents 95% CI. Patients 
aged between 80-85 years were excluded from this analysis due to lower 
number of patients (n = 21).
Figure 2. Percentage of patients with new vertebral fracture (n = 31), 
according to WHO T-score classification of BMD at different sites.
apart from the above-mentioned variables, the follo-
wing data, although not statistically significant were, 
nevertheless, of interest: a history of fragility fracture in 
the last 5 years (p = 0.172), previous vertebral fracture 
(p = 0.062), previous nonvertebral fracture (p = 0.065) 
and serum calcium concentration (p = 0.160). In the 
final model, the variable that contributed most to the 
prediction of new vertebral fracture was the lumbar spi-
ne T-score (incidence rate ratio of 1.46, 95% CI 1.22 to 
1.62, p-value of 0.001). 
DISCUSSION
It is important to emphasize that this study is not 
strictly an epidemiologic one. These data came from a 
placebo group of a randomized clinical trial, which has 
specific inclusion and exclusion criteria that may not be 
reflected in the general population. As such, we can-
not rule out an element of selection bias. Other limi-
tations refer to the fact that only the first new fracture 
during the study was taken into account. Besides, all 
participants received calcium and vitamin D during the 
protocol. On the other hand, an observational study in 
a population with known high fracture risk would be 
very difficult be obtain approval for with calcium and 
vitamin D only. 
To our knowledge, this is the first Latin America 
study to evaluate osteoporotic vertebral fracture inci-
dence assembled from centers distributed throughout 
the same country. The estimated incidence rate was 
7.7/1,000 PY. The incidence of vertebral fractures in 
postmenopausal women with low bone mass increased 
with age, being 3.5 fold higher in patients aged be-
tween 75 to 79 (incidence rate of 18.5/1,000 PY), as 
compared to the group, 60 to 64 years old (incidence 
rate of 5.3/1,000 PY). This increase in fracture risk is 
similar to The European Prospective Osteoporosis Stu-
dy (EPOS) (3), which showed an increase of 3.1 fold 
in the group aged between 75 to 79 compared to 60 to 
64 years. In addition, the results are concordant with 
the Rotterdam study (16), which found that patients 
aged 75 years or more had 2.5 fold higher vertebral 
fracture incidence than the group aged between 55 to 
65 years old. These data demonstrate the importance of 
age as a key determinant of fracture risk. 
Based on population projection from the Brazilian 
Institute of Geographic and Statistics (IBGE in Portu-
guese) (12), it is expected that the female population 
between 60 to 79 years old will triple from 2013 to 
2060. Assuming that in Brazil 2/3 of this population 
has low bone mass or osteoporosis (17) and based on 
our data, a reasonable estimate projects an increase in 
the number of new vertebral fractures from 60,000 in 
2013 to more than 188,000 in 2060. 
The estimated incidence rate of 7.7/1,000 PY 
seems to be somewhat lower than the EPOS study 
(3) (10.7/1,000 PY) and the Rotterdam study (16) 
(14.7/1,000 PY), especially if one considers that our 
population was pre-selected and had low bone mass. 
Nevertheless, these studies utilized a more stringent cri-
terion for vertebral fracture (reduction of 20% and 15% 
of vertebral height, respectively). In the EPOS Study, 
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using a more stringent criterion of 25% reduction in 
vertebra height, the incidence rate falls to 8.7/1,000 
PY. Both Rotterdam and EPOS studies used a morpho-
metric method of McCloskey-Kanis and, thus, could 
account for these different results. In our study, the 
Genant’s semiquantitative method was used to define 
new vertebral fracture. Notwithstanding a high con-
cordance between these methods in cases of moderate 
and severe fractures, morphometry is associated with a 
more false positive diagnosis of mild fractures than the 
semiquantitative approach (18,19). 
Ross and cols. studied 887 Hawaiian women of Ja-
panese ancestry, between 43 and 80 years of age, follo-
wed for up to 4.7 years (20). They found an overall 
incidence of 15.0/1,000 PY. Nevertheless, a reduction 
of 15% in vertebral height was considered as fracture, 
which is less stringent than the criterion used here of 
20%. It is important to point out, however, that our 
protocol was designed to include the first event only, 
refracturing not being taken into account. In the Rot-
terdam Study, one-fourth of all new fractures were due 
to refracture (16).
Two hundred thirty two sites from 23 different 
countries were involved in the Arzoxifene Generations 
Trial (13). In the placebo group, the incidence of new 
vertebral fractures was 4.3% in all countries, confirming 
that it was slightly higher when compared with 3.2% 
found in the Brazilian arm. The mean age was similar 
in all global regions (Europe, North America, South 
America and other), as well as in Brazil. This interesting 
comparison takes into account similar inclusion and ex-
clusion criteria, X-rays analysis to define new vertebral 
fracture as well as the same window of time. 
The overall incidence of clinical (symptomatic) ver-
tebral fracture in a population-based epidemiologic stu-
dy in Rochester was 1.45 per 1,000 person-years (21). 
It is well established that the majority of vertebral frac-
ture is asymptomatic, and literature considers that only 
one-third of them is symptomatic (4). Nevertheless, we 
found an even lower rate of this kind of fracture, with 
only one-fifth of cases symptomatic in our set. Conside-
ring this, the incidence rate of clinical vertebral fracture in 
our study is very similar to the Rochester experience (21). 
Only two studies are available on vertebral fracture 
incidence in Brazilian cohorts (22,23) with different de-
signs, and they cannot be properly compared with each 
other or with our study. One of these studies was carried 
out in an Osteoporosis Outpatient Clinic from a Scho-
ol-Hospital in Sao Paulo, and found an incidence rate 
of 41.7 fractures per 1,000 person-years, 70% of which 
were vertebral fractures (22). This rate was determined 
from 275 postmenopausal women evaluated at baseline 
and 5 years later. In that study, patients with fracture 
were older than our patients. They were at greater frac-
ture risk also because of a referral bias (a tertiary care 
center), a higher prevalence of previous fracture. Howe-
ver, risk factors for fractures were very similar to ours. 
Another Brazilian population-based study publi-
shed recently (23) found a vertebral fracture incidence 
of 40.3/1,000 person-years fracture in a population 
> 65 years living in a district of Sao Paulo, which is 
more than five times higher incidence than we found. 
In this study, women were older than ours (72.9 vs 67.1 
years old, respectively), with 70% older than 70, whe-
reas only 30% of our patients were in this older age 
range. Femoral neck BMD was substantially lower in 
that cohort than in ours (0.656 vs 0.714 g/cm2, res-
pectively). Other differences included a high refracture 
rate of 43.2% in their patients. On the other hand, both 
studies found similar risk factors for vertebral fracture 
in postmenopausal Brazilian population (age, lumbar 
spine BMD and previous fracture). Another point that 
is noteworthy is that during the Arzoxifene Generations 
Trial, all postmenopausal women received supplemen-
tation with calcium (500 mg daily) and vitamin D (400 
to 600 IU), which may have reduced incidence of frac-
tures. Notwithstanding, a meta-analysis showed that 
calcium and vitamin D supplementation was ineffective 
in preventing vertebral fractures (24).
 Apart of age and previous fracture, the lumbar spi-
ne T-score was the most relevant risk factor for a new 
vertebral fracture. This strong association between 
lumbar spine T-score and vertebral fracture may be due 
to the rapid loss of trabecular bone in the first years 
after menopause, being revealed most clearly at a trabe-
cular site (i.e. lumbar spine). Other point that may help 
to account for this strong association is that our relati-
vely young population (< 70 years) is less likely to have 
osteoarthritis, which can artifactually overestimate spi-
ne BMD. Interestingly, we did not find any association 
between femoral neck or total hip BMD with vertebral 
fracture (Figure 2). Local femoral cortical bone thick-
ness and density declines later than trabecular bone of 
the lumbar spine. In this regard, it is not surprising that 
femoral BMD is less predictor of vertebral fracture in 
younger patients. This question could be evaluated in 
future studies, using FRAX with and without femoral 
neck BMD input. 
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An interesting finding to be underscored is the ob-
servation that stratum A had 90.3% (n = 28 in 31) of 
new fractures, illustrating not only the importance of 
osteoporosis but also of osteopenia with previous frac-
ture as risk factors for a new vertebral fracture.
One of the strengths of this study is that it encom-
passes many different regions in Brazil over a reasona-
bly long period of time. It constitutes the first study 
of its kind in Latin America. Another strength is that 
vertebral fractures were analyzed at a specialized, inde-
pendent, central facility. 
In conclusion, in this selected Brazilian postmeno-
pausal population with osteopenia or osteoporosis, the 
incidence rate of vertebral fracture was 7.7 per 1,000 
person-years, increasing from 5.3 in patients aged be-
tween 60 to 64 years old to 18.5 in older than 75 to 79 
years old. Age and previous fractures were associated 
with new vertebral fracture, but lumbar spine BMD was 
the most important predictor. For each SD decreased at 
BMD in lumbar spine T-score, there was an almost 50% 
increase in the risk of fracture. 
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